Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03993418
Other study ID # 4812
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2019
Est. completion date December 10, 2019

Study information

Verified date December 2019
Source University of Manchester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate whether long-term consumption of the low calorie sweetener stevia affects glucose tolerance in healthy participants. With regard to this aim, we will recruit 2 study groups, the stevia group where participants will be required to add stevia drops twice daily in their habitual drinks and the control group where participants will be asked not to change anything in their diet and lifestyle.


Description:

Excess consumption of caloric sweeteners contributes to the alarming rates of overweight and obesity, whereas non-nutritive sweeteners (NNS) are non-caloric alternatives offering sensory and health benefits. NNS are widely used to moderate energy intake and postprandial glycaemia, but there is controversial evidence about their role and effects. Stevia, a natural NNS, has been suggested to assist with glucose regulation but data on glucose tolerance after daily consumption of stevia are lacking. The investigators plan to undertake a pilot randomized 2-parallel arm open-label 12-week trial, where participants will start consuming stevia with their habitual drinks. Thirty healthy volunteers (not habitual consumers of stevia or other NNS) will be recruited. The intervention group (n=15) will consume 5 drops of stevia with their habitual drinks twice daily whereas the control group (n=15) will not be required to change anything in their diet, but avoid consuming NNS or diet beverages for the study duration.

Key measures in glucose homeostasis including glucose response to an oral glucose tolerance test will be performed before and after the intervention period. Serum and plasma samples will be stored for potential analysis of insulin and gut hormones levels.

Participants will have to attend 3 study visits, visit week 0, visit week 6 and visit week 12, but the primary outcome will be assessed in visit week 0 and visit week 12.

Participants will be weighed; dietary intake, physical activity and appetite will be also assessed. Faecal samples will be collected and gut microbiome analysis may be performed. Gut microbiome has been considered to be a key linked topic, since it has been suggested that saccharin consumption may induce glucose intolerance in humans through alterations in gut microbiota in humans.

The trial will assess whether regular use of stevia in realistic amounts has any effects on glucose homeostasis, and aims to elucidate our understanding of long-term physiological effects of NNS.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 10, 2019
Est. primary completion date December 10, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Age 18-40 years

- BMI 18.5-25 kg/m2

- No or low NNS consumers (up to 1 can of diet soda per week or 1 sachet of NNS per week)

- DEBQ for restraint eating = 3

- Healthy - general good health

- Not taking medications that affect metabolism or appetite (i.e. thiazide diuretics, glucocorticoids or beta blockers)

- Stable weight, = 5 kg last 12 months

- Fasting blood glucose =6.0 mmol/L

- Willing to comply with the study protocol

- No self-reported food allergy or intolerance to foods supplied during the study

- The participant is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

- The participant is able to read, comprehend and record information written in English.

- A signed and dated written informed consent is obtained from the participant.

Exclusion Criteria:

- Age under 18 years or over 40 years old.

- BMI >25 kg/m2 and <18.5kg/m2

- Participants who are not willing to comply with study procedures (including expression of dislike for NNS)

- Habitual NNS consumers, >1 can of diet beverage or >1 sachet of low calorie sweeteners per week.

- Fasting blood glucose measured > 6 mmol/L

- Subjects who are currently dieting and having ceased a diet in < 4 weeks

- DEBQ score for restraint eating > 3

- Subjects who follow special diets for weight maintenance, such as Atkins Diet, Weight Watchers, gluten-free diet, The Zone diet, Vegetarian Diet, Raw Food Diet etc.

- Vegetarians, vegans

- Subjects who take recreational substances such as cannabis.

- Presence of any chronic condition requiring medication that might affect our results (e.g. diabetes, mental diseases, gastrointestinal diseases)

- Subjects with eating disorders (binge eating disorder, bulimia etc)

- Subjects who are currently experiencing anxiety or depression

- Participants who drink alcohol more than the NHS guidelines (14 units per week)

- >10 h of vigorous physical activities per week and/or planning to increase/decrease physical activity levels in the next months.

- Having ceased smoking in the last six months

- Female participants who are, or may be, pregnant, or currently lactating.

- Subjects who regularly consume dietary supplements for weight loss, muscle building etc.

- Subjects with food allergies or intolerances related to the study.

- Subjects who have given blood elsewhere within the last month.

- The participant cannot read, comprehend and record information written in English.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
stevia
This arm will be required to consume 5 stevia drops twice daily in habitual drinks

Locations

Country Name City State
United Kingdom University of Manchester Manchester

Sponsors (2)

Lead Sponsor Collaborator
University of Manchester Lancaster University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Physical activity Total MET-minutes per week measured via the International Physical Activity Questionnaire (IPAQ). Week 0, visit week 6 and week 12
Other Physical activity Number of steps per day. 3 days before visit week 0, visit week 6 and visit week 12 Week 0, week 6, week 12
Other Blood pressure Blood pressure will be measure on visit week 0, visit week 6 and visit week 12 Week 0, visit week 6 and week 12
Other Composition of gut microbiome Changes in gut microbiota will be measured by 16S rRNA gene sequencing. This outcome is optional and will be decided by the investigators based on the findings in the primary outcome. Week 0 and week 12
Other Fasting plasma insulin This outcome is optional and will be decided by the investigators based on the findings in the primary outcome Week 0 and week 12
Other 75g OGTT derived iAUC plasma insulin This outcome is optional and will be decided by the investigators based on the findings in the primary outcome. Week 0 and week 12
Primary Glucose response to an oral glucose tolerance test (OGTT) measured as incremental area under the curve (iAUC) blood glucose levels will be measured at baseline (0) and at 15, 30, 45, 60, 90 and 120 min after the consumption of a 75 g glucose load and iAUC will be calculated Week 0 and week 12
Secondary Change in body weight body weight will be measured on visit week 0, visit week 6 and visit week 12 Week 0, visit week 6 and week 12
Secondary Change in dietary intake participants will fill out 3 days of diet recalls before coming to all 3 study visits using Intake24 Week 0, visit week 6 and week 12
Secondary Change in waist circumference waist circumference will be measured on visit week 0, visit week 6 and visit week 12 Week 0, visit week 6 and week 12
Secondary Change in appetite Appetite questionnaires (three factor eating questionnaire, sweet food frequency questionnaire, Satiety, hunger, and food cravings - using the Control of Eating Questionnaire ) will be completed on visit week 0 and visit week 12 Week 0 and week 12
Secondary Change in fasting blood glucose Fasting blood glucose will be measured on visit week 0 and visit week 12. Week 0 and week 12
Secondary Change in the 75-OGTT 2-hour blood glucose 75g OGTT 2-h blood glucose will be measured on visit week 0 and visit week 12. Week 0 and week 12
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2